back neutral lenvima support share
action upgrad eisai under-perform neutral reduc
target price potenti return although share
trade previou target price anticip linger effect
discontinu develop aducanumab alzheim diseas
ad expect upsid share price limit also
introduc estim
invest overview expect eisai maintain op averag
due earn contribut anti-cancer
lenvima sale grow joint develop market
agreement merck lenvima sale grow steadili
collabor expect eisai receiv one-tim payment
plu multipl mileston payment drug approv
addit indic result phase trial ad pipelin drug
elenbecestat schedul releas
elenbecestat news ad drug
previous share-pric catalyst expect littl news time
think eisai share price may reflect lenvima profit contribut
catalysts/risk posit catalyst includ progress develop
ad drug higher earn contribut lenvima potenti
discontinu develop elenbecestat major risk
valuat target price base forward price-to-earnings
appli ep forecast previous use
valuat metric
chang tp
number share mn
price month
under-perform neutral
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price may upsid rate under-perform neutral target price
profit tax
issuanc retir stock
net chang cash
number share mn
cash equival
dementia lewi bodi
compani mention price
